Immunogenic Bordetella Bronchiseptica Compositions
Provided herein are compositions, combinations, and methods comprising Bordetella bronchiseptica and isolated pertactin, which are effective in treating or preventing respiratory infections, such as kennel cough, in animals.
1 . An immunogenic composition comprising Bordetella bronchiseptica and an isolated pertactin antigen.
2 . The immunogenic composition of claim 1 , wherein said pertactin antigen is a Bordetella bronchiseptica protein.
3 . The immunogenic composition of claim 2 , wherein said pertactin antigen is a recombinant p68 protein.
4 . The immunogenic composition of claim 1 , wherein the Bordetella bronchiseptica is a bacterin or a bacterial extract.
5 . The immunogenic composition of claim 1 wherein said composition is non-adjuvanted.
6 . The immunogenic composition of claim 1 wherein said pertactin antigen is present at between about 1 μg and about 30 μg.
7 . The immunogenic composition of claim 1 wherein said pertactin antigen is prepared by solubilizing pertactin inclusion bodies in urea and wherein the composition is substantially free of aggregates of pertactin antigens.
8 . The immunogenic composition of claim 1 wherein the pertactin antigen is lipidated.
9 . The immunogenic composition of claim 1 wherein said composition further comprises a diluent or excipient for parenteral administration to a dog.
10 . The immunogenic composition of claim 1 wherein said composition further comprises an isolated Bsp22 antigen, optionally lipidated.
11 . The immunogenic composition of claim 1 wherein said composition further comprises an antigen from a canine respiratory pathogen selected from the group consisting of: canine parainfluenza virus (CPIV), canine adenovirus-2 (CAV-2), canine respiratory coronavirus (CRCoV), Mycoplasma cynos ( M. Cynos ) and canine influenza virus (CIV).
12 . The immunogenic composition of claim 11 , wherein said composition comprises at least two, three or four of the antigens from the canine respiratory pathogen.
13 . The immunogenic composition of claim 11 , wherein said composition comprises antigens from canine parainfluenza virus (CPIV), canine adenovirus-2 (CAV-2), canine respiratory coronavirus (CRCoV) and canine influenza virus (CIV).
14 . An immunogenic composition comprising a plurality of recombinant p68 pertactin antigens, wherein said composition is substantially free of p68 aggregates.
15 . The immunogenic composition of claim 14 , wherein said plurality of recombinant p68 pertactin antigens are prepared by solubilizing pertactin inclusion bodies in urea and optionally purifying by column chromatography.
16 . A method of treating or preventing infection from a canine respiratory pathogen in a dog by administering to the dog the immunogenic composition of claim 1 .
17 . The method of claim 16 , wherein said composition prevents infection from said canine respiratory pathogen in said dog for a period of 6-months or more.
18 . The method of claim 16 , wherein the canine respiratory pathogen is Bordetella bronchiseptica.
19 . The method of claim 18 , wherein the canine respiratory pathogen further comprises at least one, two, three or four of: canine parainfluenza virus (CPIV), canine adenovirus-2 (CAV-2), canine respiratory coronavirus (CRCoV) and canine influenza virus (CIV).
20 . The method of claim 16 , for treatment or prevention of canine infectious respiratory disease complex (CIRDC), wherein the composition treats or prevents infection from a plurality of said pathogens.